Quick Answer
Edgewise Therapeutics, Inc. reported Diluted EPS of $1.63 per share (loss) for fiscal year 2025.
Edgewise Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.63 | -12.4% |
| 2024 | -$1.45 | +7.6% |
| 2023 | -$1.57 | — |
- Edgewise Therapeutics, Inc. showed a decrease of -12.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Edgewise Therapeutics, Inc.’s diluted eps has declined by 3.8% (from $1.57 per share (loss) to $1.63 per share (loss)).
- The most recent figure is from Edgewise Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: